企業プロフィール
Boston Scientific 株価・ニュース・カタリスト
- ティッカー:
- BSX
- 取引所:
- NYSE
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
51.43 USD (-0.77%)
終値
最終更新: 2026年8月17日
70.9B USD
時価総額
株価変動の要因
As of Aug 17, 2026, BSX closed down 0.77% at $51.43. No new same-company headline was identified in the current news window.
企業概要
Global Medical Technology Platform
Boston Scientific is a global medical technology company with products spanning cardiovascular care, endoscopy, urology, neuromodulation, interventional oncology, respiratory care, and gastrointestinal medicine. Its portfolio centers on high-performance devices and minimally invasive therapies designed to improve clinical outcomes while reducing the burden on healthcare systems.
Electrophysiology Franchise
Electrophysiology is a major innovation area for Boston Scientific. The FARAPULSE pulsed field ablation system has demonstrated advantages over antiarrhythmic drug therapy in persistent atrial fibrillation, while the FARAFLEX Mapping and PFA Catheter extends the platform toward integrated cardiac mapping and ablation.
Coronary, Structural Heart, and Embolization
The company also continues to broaden its interventional portfolio. Recent activity includes positive pivotal evidence for the SEISMIQ coronary intravascular lithotripsy catheter, FDA clearance of the TruSelect 2.6 Microcatheter, and strategic exposure to the SIEGEL transcatheter aortic valve replacement system through MiRus.
MedSurg Businesses
Outside cardiovascular care, Boston Scientific’s MedSurg segment provides technologies for endoscopy, urology, neuromodulation, and other minimally invasive procedures. This business mix reduces dependence on any single therapeutic area and gives the company multiple channels for new-product adoption.
Diversified Operating Base
Boston Scientific operates through its Cardiovascular and MedSurg segments, with additional businesses including Urology and Neuromodulation. The company expands its platform through internal R&D, strategic investments, and acquisition options, including its investment in MiRus and potential rights to acquire the SIEGEL TAVR business.
今後のカタリスト
- Enrollment has begun in the pivotal FARADIGM trial evaluating the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter in patients with paroxysmal or persistent atrial fibrillation.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。